Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences: B. Ri...
Marinus Pharmaceuticals (MRNS) trades 1.2% higher premarket after appointing Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan to the newly created position of VP, Sales.The appointments indicate the company's planning for potential comme...
J&J veteran Steven Pfanstiel named as Chief Financial Officer Lisa Lejuwaan to build out launch strategy as Vice President of Sales Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Saraswathy (“Sara”) Nochur, Ph.D., to its Board of Directors. “...
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2020 Results Earnings Conference Call March 9, 2021, 8:30 AM ET Company Participants Sasha Damouni Ellis - Vice President, Investor Relations and Corporate Communications Dr. Scott Braunstein - Chief Executive Officer Dr. Joe Hulihan - Chief Medical Off...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Marinus Pharmaceuticals (MRNS): Q4 GAAP EPS of -$0.55 misses by $0.05.Revenue of $1.54M beats by $0.34M.Press Release For further details see: Marinus Pharmaceuticals EPS misses by $0.05, beats on revenue
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17) Interim efficacy and safety evaluation of the CALM Study (open label Phase 2 trial) desi...
Updated logo and brand identity highlight Marinus’ focus on commitment, innovation and community as a leader in rare epilepsies Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that Scott Braunstein, M.D., Chief Executive Officer and Joseph Hulihan, M.D., Chief Medical Officer will p...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...